Once-daily administration of intranasal corticosteroids for allergic rhinitis: A comparative review of efficacy, safety, patient preference, and cost

American Journal of Rhinology

Volumn 21, Issue 1, 2007, Pages 70-79

  Herman, Howard ^a  

^a ENT of Georgia   (United States)

Author keywords

Adherence; Allergic rhinitis; Corticosteroids; Efficacy; Intranasal; Patient preference; Safety

Indexed keywords

ANTIHISTAMINIC AGENT; BECLOMETASONE DIPROPIONATE; BENZALKONIUM CHLORIDE; BUDESONIDE; CARBOXYMETHYLCELLULOSE; CHROMONE DERIVATIVE; CITRATE SODIUM; CITRIC ACID; CORTICOSTEROID; DECONGESTIVE AGENT; EDETATE DISODIUM; EXCIPIENT; FLUNISOLIDE; FLUTICASONE PROPIONATE; GLUCOSE; GLYCEROL; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MICROCRYSTALLINE CELLULOSE; MOMETASONE FUROATE; NASACORT AQ; PHENETHYL ALCOHOL; PLACEBO; POLYSORBATE 80; TRIAMCINOLONE ACETONIDE; UNCLASSIFIED DRUG;

ALLERGIC RHINITIS; AQUEOUS SOLUTION; CLINICAL TRIAL; CORTICOSTEROID THERAPY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG PREFERENCE; DRUG SAFETY; DRUG TOLERABILITY; ENDOCRINE DISEASE; GROWTH RETARDATION; HAY FEVER; HUMAN; HYDROCORTISONE URINE LEVEL; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; NOSE CONGESTION; PATIENT ATTITUDE; PATIENT COMPLIANCE; PERENNIAL RHINITIS; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; REVIEW; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, INTRANASAL; COST-BENEFIT ANALYSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; GLUCOCORTICOIDS; HUMANS; PATIENT SATISFACTION; RHINITIS, ALLERGIC, PERENNIAL; TREATMENT OUTCOME;

EID: 33846930674     PISSN: 10506586     EISSN: None     Source Type: Journal    
DOI: 10.2500/ajr.2007.21.2896     Document Type: Review

References (73)

1. Dykewicz MS, Fineman S, Skoner DP, et al. Diagnosis and management of rhinitis: Complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma, and Immunology. American Academy of Allergy, Asthma, and Immunology. Ann Allergy Asthma Immunol 81:478-518, 1998.
2. Sly RM. Changing prevalence of allergic rhinitis and asthma. Ann Allergy Asthma Immunol 82:233-248, 1999.
3. Spector SL. Overview of comorbid associations of allergic rhinitis. J Allergy Clin Immunol 99:S773-S780, 1997.
4. Bousquet J, Bullinger M, Fayol C, et al. Assessment of quality of life in patients with perennial allergic rhinitis with the French version of the SF-36 Health Status Questionnaire. J Allergy Clin Immunol 94:182-188, 1994.
5. Ross RN. The costs of allergic rhinitis. Am J Managed Care 2:285-290, 1996.
6. McMenamin P. Costs of hay fever in the United States in 1990. Ann Allergy 73:35-39, 1994.
7. Nash DB, Sullivan SD, and Mackowiak J. Optimizing quality of care and cost effectiveness in treating allergic rhinitis in a managed care setting. Am J Manag Care 6:S3-S15, S19-S20, 2000.
8. Bousquet J, Van Cauwenberge P, Khaltaev N, et al. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 108:S147-S334, 2001.
9. van Cauwenberge P, Bachert C, Passalacqua G, et al. for the European Academy of Allergology and Clinical Immunology. Consensus statement on the treatment of allergic rhinitis. European Academy of Allergology and Clinical Immunology. Allergy 55:116-134, 2000.
10. Nathan RA. Pharmacotherapy for allergic rhinitis: A critical review of leukotriene receptor antagonists compared with other treatments. Ann Allergy Asthma Immunol 90:182-190, 2003.
11. Nielsen LP, Mygind N, and Dahl R. Intranasal corticosteroids for allergic rhinitis: Superior relief? Drugs 61:1563-1579, 2001.
12. 1, receptor antagonists in allergic rhinitis: Systematic review of randomised controlled trials. BMJ 317:1624-1629, 1998.
13. 1 receptor antagonists for the treatment of allergic rhinitis: A systematic review with meta-analysis. Ann Allergy Asthma Immunol 89:479-484, 2002.
14. Viner AS, and Jackman N. Retrospective survey of 1271 patients diagnosed as perennial rhinitis. Clin Allergy 6:251-259, 1976.
15. Storms WW. Rethinking our approach to allergic rhinitis management. Ann Allergy Asthma Immunol 88:30-35, 2002.
16. LaForce C. Use of nasal steroids in managing allergic rhinitis. J Allergy Clin Immunol 103:S388-S394, 1999.
17. Corren J. Intranasal corticosteroids for allergic rhinitis: How do different agents compare? J Allergy Clin Immunol 104:S144-S149, 1999.
18. Dupclay L Jr, and Doyle J. Assessment of intranasal corticosteroid use in allergic rhinitis: Benefits, costs, and patient preferences. Am J Manag Care 8:S335-S340, 2002.
19. Norman P. Outlook for the allergic rhinitis market through 2011. Decision Resources 17.11-17.19, Dec. 3, 2002.
20. Reissman D, Price T, and Leibman CW. Cost efficiency of intranasal corticosteroid prescribing patterns in the management of allergic rhinitis. J Manag Care Pharm 10:S9-S13, 2004.
21. Creticos P, Fireman P, Settipane G, et al. Intranasal budesonide aqueous pump spray (Rhinocort aqua) for the treatment of seasonal allergic rhinitis. Rhinocort Aqua Study Group. Allergy Asthma Proc 19:285-294, 1998.
22. Andersson M, Svensson C, Persson C, et al. Dose-dependent effects of budesonide aqueous nasal spray on symptoms in a daily nasal allergen challenge model. Ann Allergy Asthma Immunol 85:279-283, 2000.
23. Day JH, Briscoe MP, Rafeiro E, et al. A single-dose of budesonide 64 μg (Rhinocort Aqua) is effective for severe allergic rhinitis symptoms in a controlled pollen exposure setting. J Allergy Clin Immunol 107:S313, 2001 (Abs 1024).
24. Day JH, Briscoe MP, Rafeiro E, et al. Onset of action of intranasal budesonide (Rhinocort Aqua) in seasonal allergic rhinitis studied in a controlled exposure model. J Allergy Clin Immunol 105:489-494, 2000.
25. Foresi A, Pelucchi A, Gherson G, et al. Once daily intranasal fluticasone propionate (200 micrograms) reduces nasal symptoms and inflammation but also attenuates the increase in bronchial responsiveness during the pollen season in allergic rhinitis. J Allergy Clin Immunol 98:274-282, 1996.
26. Nathan RA, Bronsky EA, Fireman P, et al. Once daily fluticasone propionate aqueous nasal spray is an effective treatment for seasonal allergic rhinitis. Ann Allergy 67:332-338, 1991.
27. Dolovich J, Wong AG, Chodirker WB, et al. Multicenter trial of fluticasone propionate aqueous nasal spray in ragweed allergic rhinitis. Ann Allergy 73:147-153, 1994.
28. LaForce CF, Dockhorn RJ, Findlay SR, et al. Fluticasone propionate: An effective alternative treatment for seasonal allergic rhinitis in adults and adolescents. J Fam Pract 38:145-152, 1994.
29. Bronsky EA, Aaronson DW, Berkowitz RB, et al. Dose ranging study of mometasone furoate (Nasonex) in seasonal allergic rhinitis. Ann Allergy Asthma Immunol 79:51-56, 1997.
30. Gawchik S, Goldstein S, Prenner B, et al. Relief of cough and nasal symptoms associated with allergic rhinitis by mometasone furoate nasal spray. Ann Allergy Asthma Immunol 90:416-421, 2003.
31. Berkowitz RB, Roberson S, Zora J, et al. Mometasone furoate nasal spray is rapidly effective in the treatment of seasonal allergic rhinitis in an outdoor (park), acute exposure setting. Allergy Asthma Proc 20:167-172, 1999.
32. Berkowitz RB, Bernstein DI, LaForce C, et al. Onset of action of mometasone furoate nasal spray (NASONEX) in seasonal allergic rhinitis. Allergy 54:64-69, 1999.
33. Munk ZM, LaForce C, Furst JA, et al. Efficacy and safety of triamcinolone acetonide aqueous nasal spray in patients with seasonal allergic rhinitis. Ann Allergy Asthma Immunol 77:277-281, 1996.
34. Settipane G, Korenblat PE, Winder J, et al. Triamcinolone acetonide aqueous nasal spray in patients with seasonal ragweed allergic rhinitis: A placebo-controlled, double-blind study. Clin Ther 17:252-263, 1995.
35. Gross G, Jacobs RL, Woodworth TH, et al. Comparative efficacy, safety, and effect on quality of life of triamcinolone acetonide and fluticasone propionate aqueous nasal sprays in patients with fall seasonal allergic rhinitis. Ann Allergy Asthma Immunol 89:56-62, 2002.
36. Berger WE, Kaiser H, Gawchik SM, et al. Triamcinolone acetonide aqueous nasal spray and fluticasone propionate are equally effective for relief of nasal symptoms in patients with seasonal allergic rhinitis. Otolaryngol Head Neck Surg 129:16-23, 2003.
37. Ahlström-Emanuelsson C, Persson CG, Svensson C, et al. Establishing a model of seasonal allergic rhinitis and demonstrating dose-response to a topical glucocorticosteroid. Ann Allergy Asthma Immunol 89:159-165, 2002.
38. Stern MA, Dahl R, Nielsen LP, et al. A comparison of aqueous suspensions of budesonide nasal spray (128 micrograms and 256 micrograms once daily) and fluticasone propionate nasal spray (200 micrograms once daily) in the treatment of adult patients with seasonal allergic rhinitis. Am J Rhinol 11:323-330, 1997.
39. Meltzer EO. Clinical and antiinflammatory effects of intranasal budesonide aqueous pump spray in the treatment of perennial allergic rhinitis. Ann Allergy Asthma Immunol 81:128-134, 1998.
40. Banov CH, Woehler TR, LaForce CF, et al. Once daily intranasal fluticasone propionate is effective for perennial allergic rhinitis. Ann Allergy 73:240-246, 1994.
41. van As A, Bronsky EA, Dockhorn RJ, et al. Once daily fluticasone propionate is as effective for perennial allergic rhinitis as twice daily beclomethasone dipropionate. J Allergy Clin Immunol 91:1146-1154, 1993.
42. Drouin M, Yang WH, Bertrand B, et al. Once daily mometasone furoate aqueous nasal spray is as effective as twice daily beclomethasone dipropionate for treating perennial allergic rhinitis patients. Ann Allergy Asthma Immunol 77:153-160, 1996.
43. Storms W, Bronsky E, Findlay S, et al. Once daily triamcinolone acetonide nasal spray is effective for the treatment of perennial allergic rhinitis. Ann Allergy 66:329-334, 1991.
44. Kobayashi RH, Beaucher WN, Koepke JW, et al. Triamcinolone acetonide aqueous nasal spray for the treatment of patients with perennial allergic rhinitis: A multicenter, randomized, double-blind, placebo-controlled study. Clin Ther 17:503-513, 1995.
45. Day J, and Carrillo T. Comparison of the efficacy of budesonide and fluticasone propionate aqueous nasal spray for once daily treatment of perennial allergic rhinitis. J Allergy Clin Immunol 102:902-908, 1998.
46. Bende M, Carrillo T, Vóna I, et al. A randomized comparison of the effects of budesonide and mometasone furoate aqueous nasal sprays on nasal peak flow rate and symptoms in perennial allergic rhinitis. Ann Allergy Asthma Immunol 88:617-623, 2002.
47. Mandl M, Nolop K, and Lutsky BN. Comparison of once daily mometasone furoate (Nasonex) and fluticasone propionate aqueous nasal sprays for the treatment of perennial rhinitis. 194-079 Study Group. Ann Allergy Asthma Immunol 79:370-378, 1997.
48. Wilson AM, McFarlane LC, and Lipworth BJ. Effects of repeated once daily dosing of three intranasal corticosteroids on basal and dynamic measures of hypothalamic-pituitary-adrenal-axis activity. J Allergy Clin Immunol 101:470-474, 1998.
49. Wilson AM, Sims EJ, McFarlane LC, et al. Effects of intranasal corticosteroids on adrenal, bone, and blood markers of systemic activity in allergic rhinitis. J Allergy Clin Immunol 102:598-604, 1998.
50. Grahnen A, Eckernas SA, Brundin RM, et al. An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers. Br J Clin Pharmacol 38:521-525, 1994.
51. Lonnebo A, Grahnen A, Jansson B, et al. An assessment of the systemic effects of single and repeated doses of inhaled fluticasone propionate and inhaled budesonide in healthy volunteers. Eur J Clin Pharmacol 49:459-463, 1996.
52. Thorsson L, Dahlstrom K, Edsbacker S, et al. Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects. Br J Clin Pharmacol 43:155-161, 1997.
53. Naclerio RM, Baroody FM, Bidani N, et al. A comparison of nasal clearance after treatment of perennial allergic rhinitis with budesonide and mometasone. Otolaryngol Head Neck Surg 128:220-227, 2003.
54. Mahadevia PJ, Shah S, Leibman C, et al. Patient preferences for sensory attributes of intranasal corticosteroids and willingness to adhere to prescribed therapy for allergic rhinitis: A conjoint analysis. Ann Allergy Asthma Immunol 93:345-350, 2004.
55. Gerson I, Green L, and Fishken D. Patient preference and sensory comparisons of nasal spray allergy medications. J Sens Stud 14:491-496, 1999.
56. Bachert C, and El-Akkad T. Patient preferences and sensory comparisons of three intranasal corticosteroids for the treatment of allergic rhinitis. Ann Allergy Asthma Immunol 89:292-297, 2002.
57. Stokes M, Amorosi SL, Thompson D, et al. Evaluation of patients' preferences for triamcinolone acetonide aqueous, fluticasone propionate, and mometasone furoate nasal sprays in patients with allergic rhinitis. Otolaryngol Head Neck Surg 131:225-231, 2004.
58. Shah SR, Miller C, Pethick N, et al. Two multicenter, randomized, single-blind, single-dose, crossover studies of specific sensory attributes of budesonide aqueous nasal spray and fluticasone propionate nasal spray. Clin Ther 25:2198-2214, 2003.
59. Lennox RD, Fowler I, Gore M, et al. Psychometric validation of a patient-reported sensory perception and preference instrument: The Sensory Perceptions Questionnaire. Adv Ther 21:162-172, 2004.
60. Mygind N. Glucocorticosteroids and rhinitis. Allergy 48:476-490, 1993.
61. Bernstein IL. Is the use of benzalkonium chloride as a preservative for nasal formulations a safety concern? A cautionary note based on compromised mucociliary transport. J Allergy Clin Immunol 105:39-44, 2000.
62. Stanaland BE. Once-daily budesonide aqueous nasal spray for allergic rhinitis: A review. Clin Ther 26:473-492, 2004.
63. Ståhl E, van Rompay W, Wang EC, et al. Cost-effectiveness analysis of budesonide aqueous nasal spray and fluticasone propionate nasal spray in the treatment of perennial allergic rhinitis. Ann Allergy Asthma Immunol 84:397-402, 2000.
64. Suissa S, Baltzan M, Kremer R, et al. Inhaled and nasal corticosteroid use and the risk of fracture. Am J Respir Crit Care Med 169:83-88, 2004.
65. Lindqvist N, Baile VH, Karma P, et al. Long-term safety and efficacy of budesonide nasal aerosol in perennial rhinitis. A 12-month multicentre study. Allergy 41:179-186, 1986.
66. Pipkorn U, Pukander J, Suonpaa J, et al. Long-term safety of budesonide nasal aerosol: A 5.5-year follow-up study. Clin Allergy 18:253-259, 1988.
67. Möller C, Ahlstrom H, Henricson KA, et al. Safety of nasal budesonide in the long-term treatment of children with perennial rhinitis. Clin Exp Allergy 33:816-822, 2003.
68. Möller C, Lars E, and Svensson I. Nasal budesonide to children for 5 years. Allergy Clin Immunol News 2:427, 1994 (Abs 1546).
69. Murphy K, Uryniak T, Simpson B, et al. Recommended once-daily dose of budesonide aqueous nasal spray (Rhinocort Aqua) does not suppress growth velocity in pediatric patients with perennial allergic rhinitis. J Allergy Clin Immunol 113:S175, 2004.
70. USFDA labeling and prescription drug advertising: Content and format for labeling for human prescription drugs. Fed Regist 44:37434-37467, 1979.
71. Norjavaara E, and de Verdier MG. Normal pregnancy outcomes in a population-based study including 2,968 pregnant women exposed to budesonide. J Allergy Clin Immunol 111:736-742, 2003.
72. Kallen B, Rydhstroem H, and Aberg A. Congenital malformations after the use of inhaled budesonide in early pregnancy. Obstet Gynecol 93:392-395, 1999.
73. Kallen A, and Thorsson L. Drug disposition analysis: A comparison between budesonide and fluticasone. J Pharmacokinet Pharmacodyn 30:239-256, 2003.